[New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
Frölich
L
L
Zentralinstitut für Seelische Gesundheit Mannheim, Universität Heidelberg. froelich@zi-mannheim.de
Schmitt
B
B
Calabrese
P
P
Diener
H
H
Förstl
H
H
Gertz
H J
HJ
Hallauer
J F
JF
Hampel
H
H
Ihl
R
R
Rieke
K
K
Riepe
M
M
Supprian
T
T
D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008559:Memantine / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000187:drug effects; D012720:Severity of Illness Index; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D016194:Receptors, N-Methyl-D-Aspartate; D008559:Memantine